Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2023 | What does the future hold for CAR T-cells in sarcoma management?

Brian Van Tine, MD, PhD, Washington University, St. Louis, MO, describes possible advances in the field of CAR T-cell therapies for sarcoma. Following on from the anti-MAGE-A4 CAR T-cell, there is great potential for expansion across different targets and HLA types. Such therapies may additionally be indicated for other solid tumors, leading to pan-tumor cell therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.